O Rendimento de dividendos de Medicrea International SA é N/A
O rendimento de dividendos representa a razão entre os dividendos pagos aos acionistas por ação e o preço de mercado por ação durante um ano consecutivo.
The dividend yield or dividend-price ratio of a share is the dividend per share, divided by the price per share. It is also a company's total annual dividend payments divided by its market capitalization, assuming the number of shares is constant, and is often expressed as a percentage. The reciprocal of the dividend yield is the price-dividend ratio.
A higher dividend yield has been considered to be desirable among many investors. A high dividend yield can be considered to be evidence that a stock is underpriced or that the company has fallen on hard times and future dividends will not be as high as previous ones. Similarly a low dividend yield can be considered evidence that the stock is overpriced or that future dividends might be higher. Some investors may find a higher dividend yield attractive, for instance as an aid to marketing a fund to retail investors, or maybe because they cannot get their hands on the capital, which may be tied up in a trust arrangement. In contrast some investors may find a higher dividend yield unattractive, perhaps because it increases their tax bill.
Medicrea International SA designs, manufactures, and distributes spinal implants in France and internationally. It offers PASS range, a polyaxial spine system; PASS LP, a thoraco-lumbar fixation system; LigaPASS, a band connector for posterior thoracolumbar fixation; PASS TULIP, a top loading posterior fixation system; PASS DEGEN for thoracic and lumbar degenerative indications; PASS OCT, an occipito-cervico-thoracic fixation system; PASS MIS, a posterior anchoring system; PASS Antérieur that offers a range of specific implants enabling surgery using an anterior approach; IMPIX C, a sterile PEEK Optima cervical interbody device; IMPIX-C+, a sterile PEEK Optima cervical interbody device that is prefilled with bone substitute; and IMPIX-MANTA, a sterile PEEK Optima cervical interbody device that is preassembled on holder/ impactor and delivers with a disposable instrumentation kit. Its implants for cervical spine also include IMPIX-MANTA +, a sterile PEEK Optima cervical interbody device, which is prefilled with synthetic bone substitutes; and GRANVIA-C, a MRI compatible ceramic cervical disc. In addition, it provides implants for the thoracic and lumbar spine, such as IMPIX-L, a sterile PEEK Optima lumbar interbody device for posterior approach; IMPIX-TLIF, a sterile PEEK Optima lumbar interbody device for transforaminal approach with a pre-assembled PEEK control lead; IMPIX-ALIF, a sterile PEEK Optima lumbar interbody device for anterior approach; STABOLT, an anatomically-shaped anterior plate; OSMOSYS, a macroporous bone substitute; IMPIX-DLIF and IMPIX-DLIF SLIM sterile PEEK Optima lumbar interbody devices for direct or oblique lateral approach; and X-JAWS, a titanium lumbar staple to secure a lateral or an anterior cage. Its implants are designed to treat scoliosis, degenerative diseases, malformations, trauma, and tumors; and used in various traditional and surgical procedures. The company was founded in 1990 and is headquartered in Rillieux-la-Pape, France.